Humanwell Healthcare (Group) Co., Ltd. stated on November 14 in response to investor inquiries that the company has consistently focused on developing its core pharmaceutical business. It continues to advance its "core-focused" strategy, optimizing its asset structure and strengthening its competitive edge in specialized sectors.
In the first three quarters of 2025, the company reported net profit attributable to shareholders of 1.689 billion yuan, a year-on-year increase of 6.22%. By the end of Q3 2025, its asset-liability ratio dropped to 40.53%, reflecting continuous improvement in its asset structure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments